Additionally, since abnormal activation of FMS-like tyrosine kinase 3 (FLT3) is common in AML patients, the selective FLT3 inhibitor SC-203048 can work synergistically with PTL to suppress AML growth and enhance cellular apoptosis (Wang et al., 2012). Here, PNLIP is linked to acute myeloid leukemia.